Summary
Large Degree of Innovation
in Parkinsons Disease Pipeline
The “Parkinsons
disease” (PD) pipeline currently has 302 products in active development
across all stages, but a stark contrast between the mechanisms of action
employed in the current market and the pipeline is evident. Where the market
relies on symptomatic treatments that target neuromodulatory receptors, the
pipeline shows a diverse range of neuroprotective therapies targeting
dysfunctional disease processes. This diversity is partially due to the presence
of 90 first-in-class products, which accounts for 37% of the overall pipeline
therapies that disclosed their target. In an industry, market and development
landscape that favors first-in-class over non-first-in-class development in many
ways, such as through faster approval or greater revenue, this finding has
strategic implications for a wide array of market participants, both large and
small. Despite their historically high attrition rate, first-in-class therapies
that reach the market have the potential to transform and improve the PD
treatment landscape.
Alignment of
First-in-Class Molecular Target with Disease Processes and Genetics
PD is a complex and
multifaceted disease with a complex interplay between different pathological
processes. Enormous research efforts and significant technological advances have
furthered knowledge of the neuroanatomy of the basal ganglia and of the
fundamental processes underlying neurodegeneration, helped by the ongoing
identification of susceptibility genes and causative genes in familial PD.
Although the exact mechanisms that initiate onset remain unclear, these insights
have been translated into the pool of novel therapeutic targets, which may
potentially become disease-modifying therapies by aligning to the disease
processes and some genetic determinants of PD.
GBI Researchs proprietary
analysis showed substantial variation in how well the functional roles of PD
first-in-class targets align PD. Further in-depth analysis identified the most
promising first-in-class targets based on various scientific and clinical
parameters. Examining scientific and clinical data of promising first-in-class
targets showed that first-in-class status is not, in its own right, enough for a
successful product; however, the first-in-class products substantiated by
scientific and clinical evidence will be exciting future prospects with the
potential to transform the PD market.
First-in-Class Products in
Licensing and Co-development Deals
Strategic consolidation is
relatively uncommon in the PD market. Concerning first-in-class specifically,
only nine first-in-class products that are currently in development have been
involved in licensing or co-development deals since 2006. Despite the low sample
size, it is clear that the first-in-class PD products offer an attractive
investment prospect as they command much higher deal values and, on average,
deals occur earlier in development compared to non-first-in-class counterparts.
Both trends were substantiated by industry-wide data that showed that,
particularly in Phase I, first-in-class products would attract larger mean and
median total deal values. The data highlight that the first-in-class deals
landscape is different and indicates a greater chance of becoming much more
lucrative than the deals landscape for addition-to-class or advance-in-class
therapies.
A total of 81
first-in-class products that are currently in development have not yet been
entered into a licensing or co-development deal. Under a growing unmet need for
disease-modifying therapies and increasing understanding of disease processes
allowed by technological advances, there are numerous opportunities for
strategic alliances to bolster a first-in-class portfolio or fund clinical
development. Some of these first-in-class products are supported by promising
scientific and clinical data, making them attractive prospects as both
therapeutics and investment opportunities.
Scope
The report analyzes
innovation in PD in the context of the overall pipeline and current market
landscape. It also analyzes the deals landscape surrounding first-in-class
products and pinpoints in-licensing opportunities.The report includes -
- A brief introduction to
PD, including symptoms, pathophysiology, and an overview of pharmacotherapy and
treatment algorithms
- Coverage of the changing
molecular target landscape and particular points of innovation in the pipeline
- A comprehensive review
of the pipeline for first-in-class therapies, analyzed by stage of development,
molecule type and molecular target
- Identification and
assessment of first-in-class molecular targets with a particular focus on
early-stage programs of which clinical utility has yet to be evaluated, as well
as literature reviews of novel molecular targets
- Industry-wide analysis
of first-in-class deals compared to non-first-in-class deals
- An assessment of the
licensing and co-development deal landscape for PD therapies and benchmarking of
deals comparing first-in-class and non-first-in-class-products
Reasons to buy
The report will enable
business development and enable marketing executives to strategize their product
launches by allowing them to -
- Understand the focal
shifts in molecular targets in the PD pipeline
- Understand the
distribution of pipeline programs by phase of development, molecule type and
molecular target
- Access a scientific and
clinical analysis of first-in-class developmental programs for PD, benchmarked
against non-first-in-class targets
- Assess the valuations of
licensed and co-developed PD treatments
- Access a list of the
first-in-class therapies potentially open to deal-making opportunities
Browse complete Report on:
For More Related Market
Research Reports click
here:
Healthcare Market Research ReportsAbout Aarkstore.Com
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on Market Research Reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom
No comments:
Post a Comment